β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage

[1]  K. Scearce-Levie,et al.  A Therapeutic Antibody Targeting Bace1 Inhibits Amyloid-beta Production in Vivo , 2013 .

[2]  K. Blennow,et al.  Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. , 2012, Archives of neurology.

[3]  K. Blennow,et al.  BACE1 Inhibition Induces a Specific Cerebrospinal Fluid β-Amyloid Pattern That Identifies Drug Effects in the Central Nervous System , 2012, PloS one.

[4]  James E Audia,et al.  Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor , 2011, The Journal of Neuroscience.

[5]  S. Love,et al.  A&bgr;-Degrading Enzymes: Potential for Treatment of Alzheimer Disease , 2011, Journal of neuropathology and experimental neurology.

[6]  K. Blennow,et al.  A novel pathway for amyloid precursor protein processing , 2011, Neurobiology of Aging.

[7]  Patty C. Kandalepas,et al.  The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease , 2011, Alzheimer's Research & Therapy.

[8]  K. Scearce-Levie,et al.  A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo , 2011, Science Translational Medicine.

[9]  E. Kremmer,et al.  ADAM10 is the physiologically relevant, constitutive α‐secretase of the amyloid precursor protein in primary neurons , 2010, The EMBO journal.

[10]  A. Simon,et al.  Acute γ-Secretase Inhibition of Nonhuman Primate CNS Shifts Amyloid Precursor Protein (APP) Metabolism from Amyloid-β Production to Alternative APP Fragments without Amyloid-β Rebound , 2010, The Journal of Neuroscience.

[11]  M. Citron.  Alzheimer's disease: strategies for disease modification , 2010, Nature Reviews Drug Discovery.

[12]  K. Blennow,et al.  Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease , 2010, Acta Neuropathologica.

[13]  Henrik Zetterberg,et al.  A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease , 2010, Alzheimer's Research & Therapy.

[14]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[15]  K. Blennow,et al.  Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease , 2010, Molecular Neurodegeneration.

[16]  C. Haass,et al.  Intramembrane Proteolysis by γ-Secretase* , 2008, Journal of Biological Chemistry.

[17]  Henrik Zetterberg,et al.  Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. , 2007, Journal of proteome research.

[18]  Alison R. Gregro,et al.  Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). , 2004, Journal of medicinal chemistry.

[19]  T. Tabira,et al.  Amino‐truncated amyloid β‐peptide (Aβ5‐40/42) produced from caspase‐cleaved amyloid precursor protein is deposited in Alzheimer’s disease brain , 2004 .

[20]  Min Xu,et al.  β-Secretase Cleavage at Amino Acid Residue 34 in the Amyloid β Peptide Is Dependent upon γ-Secretase Activity* , 2003, Journal of Biological Chemistry.

[21]  G. Westmeyer,et al.  Identification of a β-Secretase Activity, Which Truncates Amyloid β-Peptide after Its Presenilin-dependent Generation* , 2003, The Journal of Biological Chemistry.

[22]  R. Motter,et al.  Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .

[23]  D. Selkoe,et al.  Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids , 1992, Nature.

[24]  L S Freedman,et al.  Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. , 1978, Cancer research.

[25]  K. Blennow,et al.  A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. , 2013, Journal of Alzheimer's disease : JAD.

[26]  K. Blennow,et al.  Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[27]  K. Blennow,et al.  Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs. , 2010, Journal of Alzheimer's disease : JAD.

[28]  T. Tabira,et al.  Amino-truncated amyloid beta-peptide (Abeta5-40/42) produced from caspase-cleaved amyloid precursor protein is deposited in Alzheimer's disease brain. , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  R. Motter,et al.  Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Hardy,et al.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.

[31]  G. Glenner,et al.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.